MitoQ, the First Product Able to Penetrate Mitochondria to Deliver Antioxidants, Selected for USA's National Institute of Aging's Interventions Testing Program

Dec 07, 2015, 09:15 ET from MitoQ

LAS VEGAS, Dec. 7, 2015 /PRNewswire/ -- MitoQ, the world's first antioxidant formula able to penetrate mitochondria to deliver antioxidants in meaningful levels has been selected for the USA's National Institute of Aging's (NIA) Interventions Testing Program (ITP) -- an internationally renowned anti- aging testing program funded by the US Government, announced Randy Strong, NIA spokesperson and principal investigator for the ITP Research Program. 

Greg Macpherson, CEO of MitoQ Ltd is available for comment at the Annual World Congress on Anti-Aging Medicine; booth 8042; The Venetian & Palazzo Resorts, Las Vegas; December 10 through 13, 2015.

"Selection for the program validates a widening view within the research community that MitoQ confers anti-aging benefits by delivering the body's natural antioxidant CoQ10 to mitochondria, optimizing mitochondria and its benefits.  Until now, other sources of CoQ10 were unable to infiltrate the mitochondria and thus make a tangible difference," Macpherson explained.

"Research has shown that aging, and its associated health issues and lower energy levels, is linked to a decline in mitochondrial function. Mitochondria, our 'cellular batteries', are present in almost every cell in the body. Flooding the mitochondria with antioxidants improves the level of energy available to a cell and reduces free radical-associated cell damage," he noted. "By improving their function while reducing cell damage, we may slow down the aging process keeping all of our organs and body healthier and younger for longer."

"The NIA is part of the US National Institute of Health, an organization that invests over $30 billion per annum into health research. MitoQ was chosen for the testing program because it shows significant potential to delay or decelerate the aging process and improve general health," Macpherson noted.

Results of the ITP trial will be available in 2020 and will be published in numerous scientific journals such as Nature, Journals of Gerontology and Aging Cell.

To learn more about mitochondria and the effects of MitoQ, please view the video and web site:

MitoQ Ltd is a subsidiary of Antipodean Pharmaceuticals Inc based at Auckland's Viaduct Harbour, New Zealand. Over 50 million USD has been invested to date resulting in over 200 published papers describing MitoQ's effect across a wide range of disease models.  There are currently four MitoQ products distributed internationally; MitoQ skin serum, MitoQ 5mg Supplement, MitoQ Heart Supplement and MitoQ Blood Sugar Supplement. All are available to purchase online at  

Media Contact: 

Mora Communications Inc.
Christine Keefer Soderbergh

Annual World Congress on Anti-Aging Medicine
Booth # 8042
December 10-13, 2015

Video -